Biovica's DiviTum®TKa in four posters at SABCS

23 October 2020 - 08:00

Biovica, active in cancer diagnostics, today announced that four abstracts based on studies using the blood test DiviTum®TKa have been accepted as posters at the world's largest breast cancer symposium, SABCS, in early December.

The abstracts are based on international studies including the comprehensive US SWOG study, the European prospective PYTHIA study, the PROMISE study at the Mayo Clinic and a dosing study of palbociclib at Washington University. In all studies, DiviTum®TKa has been used to monitor the treatment effect in women with metastatic breast cancer.

“It is extremely gratifying that DiviTum®TKa is included in four posters at SABCS. It is an important validation of our test as a possible standard tool in the evaluation of treatment effect in metastatic breast cancer. The results from the SWOG study are the backbone of our ongoing FDA 510 (k) application with the goal of making the test available to US patients in early 2021,” said Anders Rylander, CEO of Biovica.

The San Antonio Breast Cancer Symposium, SABCS, runs December 8-12, 2020.

Provided by: MFN
Nasdaq First North GM (Sweden)
Biovica International AB
Biovica International AB is a biotech company. It develops and commercializes blood-based diagnostic tests with biomarkers that improve monitoring and evaluation of modern cancer treatments. Through collaboration with world- leading cancer institutes and pharmaceutical companies, it promotes the trend in healthcare for personalized treatment, with a primary focus on patient survival and benefits t...
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date